Lanreotide Zentiva (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, mainly SSTR2 and SSTR5. This binding blocks intracellular signaling pathways that trigger the release of growth hormone and other peptide hormones, thereby reducing their circulating levels.

The dose of Lanreotide Zentiva is individualized by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Healthcare providers determine the appropriate dosing schedule and any necessary adjustments.

Safety data for Lanreotide in pregnancy and lactation are limited. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the possible risk to the fetus. Breastfeeding is not recommended without medical advice.

To request Lanreotide Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Lanreotide and other agents such as octreotide share a similar mechanism of binding somatostatin receptors, but they differ in formulation, dosing frequency, and pharmacokinetic profile. Lanreotide is often administered as a long‑acting injectable, allowing less frequent dosing compared with some short‑acting alternatives.

Lanreotide Zentiva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose using a pre‑filled syringe or autoinjector, typically into the abdomen or thigh, following aseptic technique.

Serious adverse events, although rare, include acute pancreatitis, severe hyperglycaemia, anaphylactic reactions, cardiac arrhythmias, and, in patients with acromegaly, pituitary apoplexy. Prompt medical attention is required if any of these symptoms arise.

Lanreotide is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with uncontrolled diabetes, severe gallbladder disease, or those receiving other somatostatin analogues, and it should be avoided in pregnancy unless absolutely necessary.